Ask AI
Public Law117th CongressCrime and Law Enforcement
H.R. 8454Became Law

Medical Marijuana and Cannabidiol Research Expansion Act

This bill became law

Filed
Comm.
Floor
Both
Law

What it doesSummary public law (Dec 2, 2022)

Medical Marijuana and Cannabidiol Research Expansion Act

This act establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the act includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.

What just happenedDec 2, 2022

Became Public Law No: 117-215.

Who’s behind it

Rep. Blumenauer, Earl [D-OR-3](D-OR)Sponsor
10 cosponsors6 D4 R
Read on Congress.gov
10cosponsors2committees22actions1related bills11subjects
  1. Dec 2, 2022President

    Became Public Law No: 117-215.

  2. Dec 2, 2022BecameLaw36000

    Became Public Law No: 117-215.

  3. Dec 2, 2022President

    Signed by President.

  4. Dec 2, 2022BecameLaw36000

    Signed by President.

  5. Nov 29, 2022Floor

    Presented to President.

  6. Nov 29, 2022President28000

    Presented to President.

  7. Nov 17, 2022Floor

    Message on Senate action sent to the House.

  8. Nov 16, 2022Floor

    Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)

  9. Nov 16, 2022Floor17000

    Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.

  10. Jul 27, 2022IntroReferral

    Received in the Senate, read twice.

  11. Jul 26, 2022FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  12. Jul 26, 2022FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)

  13. Jul 26, 2022Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392).(text: CR H7120-7122)

  14. Jul 26, 2022FloorH30000

    Considered as unfinished business. (consideration: CR H7145-7146)

  15. Jul 26, 2022FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  16. Jul 26, 2022FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.

  17. Jul 26, 2022FloorH30000

    Considered under suspension of the rules. (consideration: CR H7120-7124)

  18. Jul 26, 2022FloorH30300

    Mr. Pallone moved to suspend the rules and pass the bill, as amended.

  19. Jul 21, 2022IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Judiciary Committee
  20. Jul 21, 2022IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  21. Jul 21, 2022IntroReferralIntro-H

    Introduced in House

  22. Jul 21, 2022IntroReferral1000

    Introduced in House

Public LawDec 2, 202249

Medical Marijuana and Cannabidiol Research Expansion Act

This act establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the act includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Passed SenateNov 16, 202255

Medical Marijuana and Cannabidiol Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Passed HouseJul 26, 202253

Medical Marijuana and Cannabidiol Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Introduced in HouseJul 21, 2022

Medical Marijuana and Cannabidiol Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Medical Marijuana and Cannabidiol Research Expansion Act — Informed